Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2022-11-14
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
$710.1m
reported value
27positions
64.6%in top 10
—no comparable previous quarter
Options: 1 call positions ($40.0m notional), 0 put positions (— notional) – listed below, not included above.
Holdings, Q3 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS IN GBT | $80.1m11.28% | — |
| MIRATI THERAPEUTICS INC MRTX | $59.4m8.36% | — |
| INCYTE CORP INCY | $51.5m7.26% | — |
| ASCENDIS PHARMA A/S SPONSORED ADR | $51.4m7.23% | — |
| LEGEND BIOTECH CORP LEGN | $43.9m6.19% | — |
| BIOGEN INC BIIB | $41.3m5.81% | — |
| IMMUNOCORE HLDGS PLC IMCR | $36.3m5.11% | — |
| VIRIDIAN THERAPEUTICS INC VRDN | $33.6m4.73% | — |
| ARGENX SE ARGX | $31.9m4.49% | — |
| UNITED THERAPEUTICS CORP DEL UTHR | $29.4m4.14% | — |
| AKERO THERAPEUTICS INC AKRO | $28.4m4.00% | — |
| BICYCLE THERAPEUTICS PLC BCYC | $27.0m3.80% | — |
| SYNDAX PHARMACEUTICALS INC SNDX | $26.1m3.67% | — |
| AXSOME THERAPEUTICS INC AXSM | $23.2m3.27% | — |
| HORIZON THERAPEUTICS PUB L HZNP | $21.7m3.06% | — |
| ALPINE IMMUNE SCIENCES INC NVLS | $15.9m2.25% | — |
| PROTHENA CORP PLC PRTA | $14.3m2.01% | — |
| ARVINAS INC ARVN | $12.6m1.78% | — |
| ESPERION THERAPEUTICS INC NE ESPR | $11.5m1.62% | — |
| MERUS N V MRUS | $11.3m1.59% | — |
| G1 THERAPEUTICS INC GTHX | $11.0m1.56% | — |
| CRINETICS PHARMACEUTICALS IN CRNX | $10.2m1.44% | — |
| OYSTER PT PHARMA INC OYST | $9.3m1.30% | — |
| TG THERAPEUTICS INC TGTX | $8.9m1.26% | — |
| POSEIDA THERAPEUTICS INC PSTX | $7.3m1.03% | — |
| VOR BIOPHARMA INC COM | $6.8m0.95% | — |
| MILESTONE PHARMACEUTICALS IN MIST | $5.8m0.82% | — |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| BIOGEN INC BIIB · Call | $40.0m150.0k shares | — |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |